Artículos por temáticas

α-Synuclein Pathology in Synucleinopathies: Mechanisms, Biomarkers, and Therapeutic Challenges

Arias-Carrión O, Guerra-Crespo M, Padilla-Godínez FJ, Soto-Rojas LO, Manjarrez E.

Int J Mol Sci. 2025 Jun 4;26(11):5405. doi: 10.3390/ijms26115405.

RNA-based therapies for neurodegenerative disease: Targeting molecular mechanisms for disease modification

Bhati V, Prasad S, Kabra A.

Mol Cell Neurosci. 2025 Jun;133:104010. doi: 10.1016/j.mcn.2025.104010. Epub 2025 May 6.

Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson's disease

Lee S, Yin L, Xiao N, Rhee TG, Lo HKY, Wong S, Fox S, Teopiz K, Lam BY, Zheng YJ, Le GH, Mansur RB, Rosenblat JD, McIntyre RS.

CNS Spectr. 2025 Jun 9;30(1):e44. doi: 10.1017/S109285292510031X.

Characterizing Parkinson's Disease Clinical and Biomarker Interactions in REM Sleep Behavior Disorder

Reddy VL, Esposito S, Renkl E, Benyakoub A, Mead K, Chrysostoum C, Patel S, Seibyl JP, Huang Y, Koo BB, Cedarbaum JM.

medRxiv [Preprint]. 2025 Jun 23:2025.05.16.25327469. doi: 10.1101/2025.05.16.25327469.

The Role of Cardiolipin in Brain Bioenergetics, Neuroinflammation, and Neurodegeneration

Bradshaw PC, Aldridge JL, Jamerson LE, McNeal C, Pearson AC, Frasier CR.

Mol Neurobiol. 2025 Jun;62(6):7022-7040. doi: 10.1007/s12035-024-04630-6. Epub 2024 Nov 19.

Aging-induced alterations in microglial cells and their impact on neurodegenerative disorders

Singh H, Gupta R, Gupta M, Ahmad A.

Mol Biol Rep. 2025 May 29;52(1):515. doi: 10.1007/s11033-025-10623-y.

Oxidative Stress: Pathological Driver in Chronic Neurodegenerative Diseases

Chong ZZ, Souayah N.

Antioxidants (Basel). 2025 Jun 9;14(6):696. doi: 10.3390/antiox14060696.

Selenium Nanoparticles as Neuroprotective Agents: Insights into Molecular Mechanisms for Parkinson's Disease Treatment

Umapathy S, Pan I, Issac PK, Kumar MSK, Giri J, Guru A, Arockiaraj J.

Mol Neurobiol. 2025 Jun;62(6):6655-6682. doi: 10.1007/s12035-024-04253-x. Epub 2024 Jun 5.

Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges

Zhou ZD, Yi L, Popławska-Domaszewicz K, Chaudhuri KR, Jankovic J, Tan EK.

Pharmacol Res. 2025 Jun;216:107770. doi: 10.1016/j.phrs.2025.107770. Epub 2025 May 8.

A novel fusion architecture for detecting Parkinson's Disease using semi-supervised speech embeddings

Adnan T, Abdelkader A, Liu Z, Hossain E, Park S, Islam MS, Hoque E.

NPJ Parkinsons Dis. 2025 Jun 20;11(1):176. doi: 10.1038/s41531-025-00956-7.

Manganese-Induced Parkinsonism: A Review of Etiologies and Treatments

Khindri NM, Maj MC.

Degener Neurol Neuromuscul Dis. 2025 Jun 6;15:65-79. doi: 10.2147/DNND.S482018. eCollection 2025.

Perineuronal nets: Role in normal brain physiology and aging, and pathology of various diseases

Zhu K, Fu Y, Zhao Y, Niu B, Lu H.

Ageing Res Rev. 2025 Jun;108:102756. doi: 10.1016/j.arr.2025.102756. Epub 2025 Apr 18.

Unlocking Parkinson's disease: the role of microRNAs in regulation, diagnosis, and therapy

Li X, Fu Q, Guo M, Du Y, Cheng Y.

Apoptosis. 2025 Jun;30(5-6):1272-1291. doi: 10.1007/s10495-025-02117-w. Epub 2025 May 1.

Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases

Katsoulaki EE, Dimopoulos D, Hadjipavlou-Litina D.

Pharmaceuticals (Basel). 2025 Jun 1;18(6):831. doi: 10.3390/ph18060831.

Neurodegeneration models in Parkinson's disease: cellular and molecular paths to neuron death

Álvarez-Luquín DD, González-Fernández RR, Torres-Velasco ME, Ichikawa-Escamilla E, Arce-Sillas A, Martínez-Martínez E, Miranda-Narvaez CL, Rodríguez-Ramírez JF, Adalid-Peralta L.

Behav Brain Funct. 2025 May 31;21(1):14. doi: 10.1186/s12993-025-00279-w.